Qureight has raised $20 million in Series B funding to expand its three-dimensional deep learning imaging portfolio and grow its commercial operations across additional therapeutic markets involving lung and heart diseases. The round was led by Molten Ventures, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension.
Molten Ventures Partner Dr. Inga Deakin and Hargreave Hale representative Anna Salim will join Qureight’s board of directors.
Qureight provides imaging services and precision endpoints for clinical trials. Its platform combines global imaging contract research organization services, proprietary AI-based lung biomarkers and data science products designed to help biopharmaceutical companies improve trial design, accelerate patient assessment and measure disease progression more precisely.
The financing will support the creation of an AI imaging laboratory that will house Qureight’s three-dimensional chest imaging foundation model. The company expects the model to reduce the amount of data and development time required to build imaging tools for additional diseases.
Qureight plans to develop new models for asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity. These capabilities will complement its existing products for lung fibrosis and expand the number of therapeutic areas supported by its regulatory-compliant, disease-agnostic clinical trial platform.
The company’s imaging CRO services support image collection and handling across clinical trial sites while enabling faster site onboarding and patient inclusion decisions. Its AI lung biomarkers quantify structural changes within specific areas of the lung, potentially helping researchers determine whether a disease is progressing or responding to treatment.
Qureight also develops synthetic control arms, which use historical and real-world data to create comparison groups for clinical studies. When scientifically and regulatorily appropriate, these tools can reduce the number of participants required in a conventional control group, lowering costs and shortening trial timelines.
The company’s technology is already being used by biopharmaceutical partners conducting clinical trials in fibrotic lung diseases. Qureight will use part of the funding to expand its commercial team and meet increasing demand for its imaging CRO services.
Qureight estimates that the global market for lung and heart clinical trials will reach $27.5 billion by 2030, representing a compound annual growth rate of 6.9% over six years.
KEY QUOTES:
“The global lung and heart clinical trials market is expected to grow to $27.5 billion by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials.”
“We are excited to bring on Molten Ventures to lead this new financing round and for Dr. Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world class team, to address a critical demand to accelerate clinical trials.”
“Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.”
Dr. Muhunthan Thillai, Co-Founder and CEO of Qureight
“Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision.”
Dr. Inga Deakin, Partner at Molten Ventures
